Scientific publications

  • Diabetes Care Dasiglucagon - Type 1 diabetes

    Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial

  • ADA Scientific Sessions Petrelintide - Obesity

    Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long Acting Amylin Analog: A Single Ascending Dose Rrial

  • Diabetalogia Dasiglucagon - Type 1 diabetes

    Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial

  • Diabetes, Obesity and Metabolism Survodutide - Obesity

    Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906

  • Molecular Metabolism Survodutide - Obesity

    BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

  • Obesity Week Petrelintide - Obesity

    Amylin Analog ZP8396 Co-formulated With Semaglutide Provides Additive Anti-obesity Effect in DIO Rat

  • Obesity Week Dapiglutide - Obesity

    Effect of Dapiglutide Alone and in Combination with the Amylin Analog ZP8396 in the Diet-induced Obesity Rat Model

  • Obesity Week ZP6590 - Obesity

    Potent Antiemetic Effect of GIP Analogue ZP6590 in Ferrets, a Gold Standard Model for Emesis Testing

  • Obesity Week ZP6590 - Obesity

    Anti-obesity Effects of GIP Analogue ZP6590 in Combination with Semaglutide in DIO Mice

  • ADA Scientific Sessions Dapiglutide - Obesity

    Dapiglutide, a Once Weekly GLP 1R/GLP 2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose Dependent Body Weight Loss Over 4 Weeks in Healthy Subjects